Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 May;60(5):433–441. doi: 10.1136/ard.60.5.433

Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies

M Abu-Shakra 1, D Buskila 1, M Ehrenfeld 1, K Conrad 1, Y Shoenfeld 1
PMCID: PMC1753641  PMID: 11302861

Abstract

OBJECTIVES—To review the autoimmune and rheumatic manifestations of patients with malignancy.
METHODS—A Medline search of all published papers using keywords related to malignancies, autoimmunity, rheumatic diseases, and paraneoplastic syndromes.
RESULTS—Patients with malignant diseases may develop autoimmune phenomena and rheumatic diseases as a result of (a) generation of autoantibodies against various autoantigens, including oncoproteins (P185, 1-myc, c-myc, c-myb), tumour suppression genes (P53), proliferation associated antigens (cyclin A, B1, D1, E; CENP-F; CDK, U3-RNP), onconeural antigens (Hu, Yo, Ri, Tr), cancer/testis antigens (MAGE, GAGE, BAGE, SSX, ESO, SCP, CT7), and rheumatic disease associated antigens (RNP, Sm). The clinical significance of the various autoantibodies is not clear. Anti-oncoprotein and anti-tumour suppression gene antigens are detected before the diagnosis of the cancer or in the early stages of the malignant disease, suggesting a potential diagnostic or prognostic role. Anti-onconeural antibodies are pathogenic and are associated with specific clinical neurological syndromes (anti-Hu syndrome and others). (b) Paraneoplastic syndromes, a wide range of clinical syndromes, including classic autoimmune rheumatic diseases that develop among patients with cancer. (c) Rheumatism after chemotherapy, a clinical entity characterised by the development of musculoskeletal symptoms after combination chemotherapy for malignancy.
CONCLUSION—Autoimmune and rheumatic features are not rare among patients with malignancies. They are the result of various diverse mechanisms and occasionally they may be associated with serious clinical entities.



Full Text

The Full Text of this article is available as a PDF (150.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abendstein B., Marth C., Müller-Holzner E., Widschwendter M., Daxenbichler G., Zeimet A. G. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer. 2000 Mar 15;88(6):1432–1437. doi: 10.1002/(sici)1097-0142(20000315)88:6<1432::aid-cncr22>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  2. Abu-Shakra M., Gladman D. D., Urowitz M. B. Malignancy in systemic lupus erythematosus. Arthritis Rheum. 1996 Jun;39(6):1050–1054. doi: 10.1002/art.1780390625. [DOI] [PubMed] [Google Scholar]
  3. Abu-Shakra M., Guillemin F., Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993 Apr;36(4):460–464. doi: 10.1002/art.1780360405. [DOI] [PubMed] [Google Scholar]
  4. Amft N., D'Cruz D. Postchemotherapy connective tissue diseases--more than just rheumatism? Lupus. 1996 Aug;5(4):255–256. doi: 10.1177/096120339600500401. [DOI] [PubMed] [Google Scholar]
  5. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  6. Ben-Mahrez K., Thierry D., Sorokine I., Danna-Muller A., Kohiyama M. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br J Cancer. 1988 Jun;57(6):529–534. doi: 10.1038/bjc.1988.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Benyahia B., Liblau R., Merle-Béral H., Tourani J. M., Dalmau J., Delattre J. Y. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999 Feb;45(2):162–167. doi: 10.1002/1531-8249(199902)45:2<162::aid-ana5>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  8. Brooks P. M. Rheumatic manifestations of neoplasia. Curr Opin Rheumatol. 1992 Feb;4(1):90–93. [PubMed] [Google Scholar]
  9. Buckanovich R. J., Darnell R. B. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol. 1997 Jun;17(6):3194–3201. doi: 10.1128/mcb.17.6.3194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Casiano C. A., Humbel R. L., Peebles C., Covini G., Tan E. M. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun. 1995 Aug;8(4):575–586. doi: 10.1016/0896-8411(95)90009-8. [DOI] [PubMed] [Google Scholar]
  11. Conrad K., Mehlhorn J. Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol. 2000 Sep;123(1):77–91. doi: 10.1159/000024426. [DOI] [PubMed] [Google Scholar]
  12. Covini G., Chan E. K., Nishioka M., Morshed S. A., Reed S. I., Tan E. M. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology. 1997 Jan;25(1):75–80. doi: 10.1002/hep.510250114. [DOI] [PubMed] [Google Scholar]
  13. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  14. Creamer P., Lim K., George E., Dieppe P. Acute inflammatory polyarthritis in association with tamoxifen. Br J Rheumatol. 1994 Jun;33(6):583–585. doi: 10.1093/rheumatology/33.6.583. [DOI] [PubMed] [Google Scholar]
  15. Dalmau J. O., Posner J. B. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 1997 Jun;24(3):318–328. [PubMed] [Google Scholar]
  16. Dalmau J., Graus F., Rosenblum M. K., Posner J. B. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992 Mar;71(2):59–72. doi: 10.1097/00005792-199203000-00001. [DOI] [PubMed] [Google Scholar]
  17. Dighiero G. Autoimmunity and B-cell malignancies. Hematol Cell Ther. 1998 Feb;40(1):1–9. [PubMed] [Google Scholar]
  18. Disis M. L., Pupa S. M., Gralow J. R., Dittadi R., Menard S., Cheever M. A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997 Nov;15(11):3363–3367. doi: 10.1200/JCO.1997.15.11.3363. [DOI] [PubMed] [Google Scholar]
  19. Drlicek M., Bianchi G., Bogliun G., Casati B., Grisold W., Kolig C., Liszka-Setinek U., Marzorati L., Wondrusch E., Cavaletti G. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol. 1997 Feb;244(2):85–89. doi: 10.1007/s004150050054. [DOI] [PubMed] [Google Scholar]
  20. Dumoulin F. L., Leifeld L., Sauerbruch T., Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999 Jun;53(5-6):242–254. doi: 10.1016/S0753-3322(99)80095-X. [DOI] [PubMed] [Google Scholar]
  21. Fathallah-Shaykh H., Wolf S., Wong E., Posner J. B., Furneaux H. M. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3451–3454. doi: 10.1073/pnas.88.8.3451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica. 1997 Jan-Feb;82(1):101–105. [PubMed] [Google Scholar]
  23. Folli F., Solimena M., Cofiell R., Austoni M., Tallini G., Fassetta G., Bates D., Cartlidge N., Bottazzo G. F., Piccolo G. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med. 1993 Feb 25;328(8):546–551. doi: 10.1056/NEJM199302253280805. [DOI] [PubMed] [Google Scholar]
  24. Gabriel S. E., Conn D. L., Phyliky R. L., Pittelkow M. R., Scott R. E. Vasculitis in hairy cell leukemia: review of literature and consideration of possible pathogenic mechanisms. J Rheumatol. 1986 Dec;13(6):1167–1172. [PubMed] [Google Scholar]
  25. Graus F., Dalmau J., Valldeoriola F., Ferrer I., Reñe R., Marin C., Vecht C. J., Arbizu T., Targa C., Moll J. W. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol. 1997 Apr;74(1-2):55–61. doi: 10.1016/s0165-5728(96)00205-6. [DOI] [PubMed] [Google Scholar]
  26. Greer J. M., Longley S., Edwards N. L., Elfenbein G. J., Panush R. S. Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore) 1988 Jul;67(4):220–230. doi: 10.1097/00005792-198807000-00003. [DOI] [PubMed] [Google Scholar]
  27. Grisold W., Drlicek M. Paraneoplastic neuropathy. Curr Opin Neurol. 1999 Oct;12(5):617–625. doi: 10.1097/00019052-199910000-00016. [DOI] [PubMed] [Google Scholar]
  28. Houghton A. N. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994 Jul 1;180(1):1–4. doi: 10.1084/jem.180.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Humphrey G. K., Goodale M. A., Bowen C. V., Gati J. S., Vilis T., Rutt B. K., Menon R. S. Differences in perceived shape from shading correlate with activity in early visual areas. Curr Biol. 1997 Feb 1;7(2):144–147. doi: 10.1016/s0960-9822(06)00058-3. [DOI] [PubMed] [Google Scholar]
  30. Imai H., Chan E. K., Kiyosawa K., Fu X. D., Tan E. M. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest. 1993 Nov;92(5):2419–2426. doi: 10.1172/JCI116848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Imai H., Fritzler M. J., Neri R., Bombardieri S., Tan E. M., Chan E. K. Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. Mol Biol Rep. 1994 Mar;19(2):115–124. doi: 10.1007/BF00997157. [DOI] [PubMed] [Google Scholar]
  32. Imai H., Ochs R. L., Kiyosawa K., Furuta S., Nakamura R. M., Tan E. M. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992 Apr;140(4):859–870. [PMC free article] [PubMed] [Google Scholar]
  33. Imai H, Furuta K, Landberg G, Kiyosawa K, Liu LF, Tan EM. Autoantibody to DNA topoisomerase II in primary liver cancer. Clin Cancer Res. 1995 Apr;1(4):417–424. [PubMed] [Google Scholar]
  34. Jäger E., Chen Y. T., Drijfhout J. W., Karbach J., Ringhoffer M., Jäger D., Arand M., Wada H., Noguchi Y., Stockert E. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998 Jan 19;187(2):265–270. doi: 10.1084/jem.187.2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Jønsson V., Wiik A., Hou-Jensen K., Christiansen M., Ryder L. P., Madsen H. O., Geisler C., Hansen M. M., Thomsen K., Vorstrup S. Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J Intern Med. 1999 Mar;245(3):277–286. doi: 10.1046/j.1365-2796.1999.0443f.x. [DOI] [PubMed] [Google Scholar]
  36. Kaden B. R., Rosse W. F., Hauch T. W. Immune thrombocytopenia in lymphoproliferative diseases. Blood. 1979 Apr;53(4):545–551. [PubMed] [Google Scholar]
  37. Kurzrock R., Cohen P. R., Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med. 1994 Feb 14;154(3):334–340. [PubMed] [Google Scholar]
  38. Leibovitch L., George J., Levi Y., Bakimer R., Shoenfeld Y. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett. 1995 Dec;48(2):129–132. doi: 10.1016/0165-2478(95)02456-5. [DOI] [PubMed] [Google Scholar]
  39. Levesque M. C., Ward F. E., Jeffery D. R., Weinberg J. B. Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. Arthritis Rheum. 1999 Mar;42(3):569–573. doi: 10.1002/1529-0131(199904)42:3<569::AID-ANR23>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  40. Liao H., Winkfein R. J., Mack G., Rattner J. B., Yen T. J. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol. 1995 Aug;130(3):507–518. doi: 10.1083/jcb.130.3.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lonardo F., Rusch V., Langenfeld J., Dmitrovsky E., Klimstra D. S. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 1999 May 15;59(10):2470–2476. [PubMed] [Google Scholar]
  42. Loprinzi C. L., Duffy J., Ingle J. N. Postchemotherapy rheumatism. J Clin Oncol. 1993 Apr;11(4):768–770. doi: 10.1200/JCO.1993.11.4.768. [DOI] [PubMed] [Google Scholar]
  43. Love P. E., Santoro S. A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med. 1990 May 1;112(9):682–698. doi: 10.7326/0003-4819-112-9-682. [DOI] [PubMed] [Google Scholar]
  44. Lubin R., Schlichtholz B., Teillaud J. L., Garay E., Bussel A., Wild C. P. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995 Dec;1(12):1463–1469. [PubMed] [Google Scholar]
  45. Lubin R., Zalcman G., Bouchet L., Trédanel J., Legros Y., Cazals D., Hirsch A., Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995 Jul;1(7):701–702. doi: 10.1038/nm0795-701. [DOI] [PubMed] [Google Scholar]
  46. Lucchinetti C. F., Kimmel D. W., Lennon V. A. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998 Mar;50(3):652–657. doi: 10.1212/wnl.50.3.652. [DOI] [PubMed] [Google Scholar]
  47. Martínez-Lavín M., Matucci-Cerinic M., Jajic I., Pineda C. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993 Aug;20(8):1386–1387. [PubMed] [Google Scholar]
  48. Marusich M. F., Furneaux H. M., Henion P. D., Weston J. A. Hu neuronal proteins are expressed in proliferating neurogenic cells. J Neurobiol. 1994 Feb;25(2):143–155. doi: 10.1002/neu.480250206. [DOI] [PubMed] [Google Scholar]
  49. Matteson E. L., Hickey A. R., Maguire L., Tilson H. H., Urowitz M. B. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol. 1991 Jun;18(6):809–814. [PubMed] [Google Scholar]
  50. Michl I., Zielinski C. C. More postchemotherapy rheumatism. J Clin Oncol. 1993 Oct;11(10):2051–2052. doi: 10.1200/JCO.1993.11.10.2051. [DOI] [PubMed] [Google Scholar]
  51. Moliterno A. R., Spivak J. L. Anemia of cancer. Hematol Oncol Clin North Am. 1996 Apr;10(2):345–363. doi: 10.1016/s0889-8588(05)70342-7. [DOI] [PubMed] [Google Scholar]
  52. Morris L. F., Lemak N. A., Arnett F. C., Jr, Jordon R. E., Duvic M. Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J. 1996 Aug;89(8):810–814. doi: 10.1097/00007611-199608000-00012. [DOI] [PubMed] [Google Scholar]
  53. Motomura M., Lang B., Johnston I., Palace J., Vincent A., Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997 Mar 20;147(1):35–42. doi: 10.1016/s0022-510x(96)05303-8. [DOI] [PubMed] [Google Scholar]
  54. Muro Y., Chan E. K., Landberg G., Tan E. M. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun. 1995 Feb 27;207(3):1029–1037. doi: 10.1006/bbrc.1995.1288. [DOI] [PubMed] [Google Scholar]
  55. Norris S. H. Paraneoplastic glomerulopathies. Semin Nephrol. 1993 May;13(3):258–272. [PubMed] [Google Scholar]
  56. O'Neill J. H., Murray N. M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988 Jun;111(Pt 3):577–596. doi: 10.1093/brain/111.3.577. [DOI] [PubMed] [Google Scholar]
  57. Odell W. D. Endocrine/metabolic syndromes of cancer. Semin Oncol. 1997 Jun;24(3):299–317. [PubMed] [Google Scholar]
  58. Old L. J., Chen Y. T. New paths in human cancer serology. J Exp Med. 1998 Apr 20;187(8):1163–1167. doi: 10.1084/jem.187.8.1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Papamichael D., Amft N., Slevin M. L., D'Cruz D. 5-Fluorouracil-induced Raynaud's phenomenon. Eur J Cancer. 1998 Nov;34(12):1983–1983. doi: 10.1016/s0959-8049(98)00184-1. [DOI] [PubMed] [Google Scholar]
  60. Paydas S., Sahin B., Zorludemir S. Sweet's syndrome accompanying leukaemia: seven cases and review of the literature. Leuk Res. 2000 Jan;24(1):83–86. doi: 10.1016/s0145-2126(99)00140-x. [DOI] [PubMed] [Google Scholar]
  61. Posner J. B., Dalmau J. O. Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med. 2000 Feb;38(2):117–122. doi: 10.1515/CCLM.2000.018. [DOI] [PubMed] [Google Scholar]
  62. Raderer M., Scheithauer W. Postchemotherapy rheumatism following adjuvant therapy for ovarian cancer. Scand J Rheumatol. 1994;23(5):291–292. doi: 10.3109/03009749409103732. [DOI] [PubMed] [Google Scholar]
  63. Rattner J. B., Rees J., Whitehead C. M., Casiano C. A., Tan E. M., Humbel R. L., Conrad K., Fritzler M. J. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med. 1997 Oct;20(5):308–319. [PubMed] [Google Scholar]
  64. Rönnblom L. E., Alm G. V., Oberg K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991 Aug 1;115(3):178–183. doi: 10.7326/0003-4819-115-3-178. [DOI] [PubMed] [Google Scholar]
  65. Saito T., Sherman W. H., Latov N. Specificity and idiotype of M-proteins that react with MAG in patients with neuropathy. J Immunol. 1983 Jun;130(6):2496–2498. [PubMed] [Google Scholar]
  66. Shapiro L. M., Mackinnon J. The resolution of hypertrophic pulmonary osteoarthropathy following treatment of subacute infective endocarditis. Postgrad Med J. 1980 Jul;56(657):513–515. doi: 10.1136/pgmj.56.657.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Sigurgeirsson B., Lindelöf B., Edhag O., Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992 Feb 6;326(6):363–367. doi: 10.1056/NEJM199202063260602. [DOI] [PubMed] [Google Scholar]
  68. Smith D. E. Additional cases of postchemotherapy rheumatism. J Clin Oncol. 1993 Aug;11(8):1625–1626. doi: 10.1200/JCO.1993.11.8.1625. [DOI] [PubMed] [Google Scholar]
  69. Sorokine I., Ben-Mahrez K., Bracone A., Thierry D., Ishii S., Imamoto F., Kohiyama M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer. 1991 Mar 12;47(5):665–669. doi: 10.1002/ijc.2910470506. [DOI] [PubMed] [Google Scholar]
  70. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000 Apr 1;60(7):1777–1788. [PubMed] [Google Scholar]
  71. Staszewski H. Hematological paraneoplastic syndromes. Semin Oncol. 1997 Jun;24(3):329–333. [PubMed] [Google Scholar]
  72. Stockert E., Jäger E., Chen Y. T., Scanlan M. J., Gout I., Karbach J., Arand M., Knuth A., Old L. J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998 Apr 20;187(8):1349–1354. doi: 10.1084/jem.187.8.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Swissa M., Amital-Teplizki H., Haim N., Cohen Y., Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer. 1990 Jun 1;65(11):2554–2558. doi: 10.1002/1097-0142(19900601)65:11<2554::aid-cncr2820651126>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  74. Swissa M., Cohen Y., Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leuk Lymphoma. 1992 May;7(1-2):117–122. doi: 10.3109/10428199209053610. [DOI] [PubMed] [Google Scholar]
  75. Sánchez-Guerrero J., Gutiérrez-Ureña S., Vidaller A., Reyes E., Iglesias A., Alarcón-Segovia D. Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. J Rheumatol. 1990 Nov;17(11):1458–1462. [PubMed] [Google Scholar]
  76. Toepfer M., Schroeder M., Unger J. W., Lochmüller H., Pongratz D., Müller-Felber W. Neuromyotonia, myocloni, sensory neuropathy and cerebellar symptoms in a patient with antibodies to neuronal nucleoproteins (anti-Hu-antibodies). Clin Neurol Neurosurg. 1999 Sep;101(3):207–209. doi: 10.1016/s0303-8467(99)00037-2. [DOI] [PubMed] [Google Scholar]
  77. Tomer Y., Sherer Y., Shoenfeld Y. Autoantibodies, autoimmunity and cancer (review). Oncol Rep. 1998 May-Jun;5(3):753–761. doi: 10.3892/or.5.3.753. [DOI] [PubMed] [Google Scholar]
  78. Trivers G. E., Cawley H. L., DeBenedetti V. M., Hollstein M., Marion M. J., Bennett W. P., Hoover M. L., Prives C. C., Tamburro C. C., Harris C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst. 1995 Sep 20;87(18):1400–1407. doi: 10.1093/jnci/87.18.1400. [DOI] [PubMed] [Google Scholar]
  79. Trivers G. E., De Benedetti V. M., Cawley H. L., Caron G., Harrington A. M., Bennett W. P., Jett J. R., Colby T. V., Tazelaar H., Pairolero P. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996 Oct;2(10):1767–1775. [PubMed] [Google Scholar]
  80. Vogelzang N. J., Bosl G. J., Johnson K., Kennedy B. J. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981 Sep;95(3):288–292. doi: 10.7326/0003-4819-95-3-288. [DOI] [PubMed] [Google Scholar]
  81. Wandl U. B., Nagel-Hiemke M., May D., Kreuzfelder E., Kloke O., Kranzhoff M., Seeber S., Niederle N. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol. 1992 Oct;65(1):70–74. doi: 10.1016/0090-1229(92)90250-r. [DOI] [PubMed] [Google Scholar]
  82. Warner E., Keshavjee al-N, Shupak R., Bellini A. Rheumatic symptoms following adjuvant therapy for breast cancer. Am J Clin Oncol. 1997 Jun;20(3):322–326. doi: 10.1097/00000421-199706000-00025. [DOI] [PubMed] [Google Scholar]
  83. Waterman S. A. Voltage-gated calcium channels in autonomic neuroeffector transmission. Prog Neurobiol. 2000 Feb;60(2):181–210. doi: 10.1016/s0301-0082(99)00025-8. [DOI] [PubMed] [Google Scholar]
  84. Yamada T., Miwa H., Ikeda K., Ohta K., Iwazaki R., Miyazaki A., Watanabe S., Hashimoto H., Futagawa S., Sato N. Polyarteritis nodosa associated with gastric carcinoma and hepatitis B virus infection. J Clin Gastroenterol. 1997 Oct;25(3):535–537. doi: 10.1097/00004836-199710000-00011. [DOI] [PubMed] [Google Scholar]
  85. Yamamoto A., Shimizu E., Ogura T., Sone S. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer. 1996 Aug 22;69(4):283–289. doi: 10.1002/(SICI)1097-0215(19960822)69:4<283::AID-IJC8>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  86. Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994 Oct;21(10):1855–1859. [PubMed] [Google Scholar]
  87. Zuckerman E., Toubi E., Golan T. D., Rosenvald-Zuckerman T., Sabo E., Shmuel Z., Yeshurun D. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995 Aug;72(2):447–451. doi: 10.1038/bjc.1995.353. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES